Stefan Engeli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stefan Engeli has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
Kerstin Gorzelniak
Franz Volhard Clinical Research Center, Charité Campus Buch, and HELIOS Klinikum Berlin, Berlin, Germany
6 shared publicationsArya M. Sharma
Cardiovascular Obesity Research & Management, Department of Medicine, McMaster University, Hamilton, Ontario, Canada
5 shared publications- Friedrich Cameron Luft
Experimental and Clinical Research Center, a joint cooperation between the Charité Medical Faculty and the Max-Delbrück Center for Molecular Medicine, Berlin, Germany
5 shared publications Jürgen Janke
†Department of Internal Medicine, Hamilton General Hospital, McMaster University, Hamilton, Ontario, Canada
3 shared publicationsMareike Feldpausch
Franz Volhard Clinical Research Center, Charité Campus Buch, and HELIOS Klinikum Berlin, Berlin, Germany
3 shared publicationsJana Böhnke
†Department of Internal Medicine, Hamilton General Hospital, McMaster University, Hamilton, Ontario, Canada
2 shared publications
Latest Publications
- 1 February 2009
- Published by The Endocrine Society in Endocrinology
- Vol. 150 (2) , 1069
Dipeptidyl-Peptidase-IV Inhibition Augments Postprandial Lipid Mobilization and Oxidation in Type 2 Diabetic Patients
Context: Dipeptidyl-peptidase-IV (DPP-4) inhibition increases endogenous GLP-1 activity resulting in improved glycemic control in patients with type 2 diabetes mellitus. The metabolic response may be explained in part by extra-pancreatic mechanisms. Objective: We tested the hypothesis that DPP-4 inhibition with vildagliptin elicits changes in adipose tissue and skeletal muscle metabolism. Design: Randomized, double blind, crossover study. Setting: Academic clinical research center. Patients: Twenty patients with type 2 diabetes, body mass index between 28 and 40 kg/m2. Intervention: Seven days treatment with the selective DPP-4 inhibitor vildagliptin or placebo. Standardized test meal on day seven. Main Outcome Measures: Venous DPP-4 activity, catecholamines, free fatty acids, glycerol, glucose, (pro)insulin; dialysate glucose, lactate, pyruvate, glycerol. Results: Fasting and postprandial venous insulin, glucose, glycerol, triglycerides and free fatty acid concentrations were not different with vildagliptin and with placebo. Vildagliptin augmented the postprandial increase in plasma norepinephrine. Furthermore, vildagliptine increased dialysate glycerol and lactate concentrations in adipose tissue while suppressing dialysate lactate and pyruvate concentration in skeletal muscle. The respiratory quotient increased with meal ingestion but was consistently lower with vildagliptin. Conclusions: Our study is the first to suggest that DPP-4 inhibition augments postprandial lipid mobilization and oxidation. The response may be explained by sympathetic activation rather than a direct effect on metabolic status.
- 1 February 2009
- Published by The Endocrine Society in Endocrinology
- Vol. 150 (2) , 1069
Dipeptidyl-Peptidase-IV Inhibition Augments Postprandial Lipid Mobilization and Oxidation in Type 2 Diabetic Patients
Context: Dipeptidyl-peptidase-IV (DPP-4) inhibition increases endogenous GLP-1 activity resulting in improved glycemic control in patients with type 2 diabetes mellitus. The metabolic response may be explained in part by extra-pancreatic mechanisms. Objective: We tested the hypothesis that DPP-4 inhibition with vildagliptin elicits changes in adipose tissue and skeletal muscle metabolism. Design: Randomized, double blind, crossover study. Setting: Academic clinical research center. Patients: Twenty patients with type 2 diabetes, body mass index between 28 and 40 kg/m2. Intervention: Seven days treatment with the selective DPP-4 inhibitor vildagliptin or placebo. Standardized test meal on day seven. Main Outcome Measures: Venous DPP-4 activity, catecholamines, free fatty acids, glycerol, glucose, (pro)insulin; dialysate glucose, lactate, pyruvate, glycerol. Results: Fasting and postprandial venous insulin, glucose, glycerol, triglycerides and free fatty acid concentrations were not different with vildagliptin and with placebo. Vildagliptin augmented the postprandial increase in plasma norepinephrine. Furthermore, vildagliptine increased dialysate glycerol and lactate concentrations in adipose tissue while suppressing dialysate lactate and pyruvate concentration in skeletal muscle. The respiratory quotient increased with meal ingestion but was consistently lower with vildagliptin. Conclusions: Our study is the first to suggest that DPP-4 inhibition augments postprandial lipid mobilization and oxidation. The response may be explained by sympathetic activation rather than a direct effect on metabolic status.
- 1 January 2009
- Published by Georg Thieme Verlag KG in Adipositas - Ursachen, Folgeerkrankungen, Therapie
- Vol. 03 (03) , 158-163
Angriffspunkt für eine antihypertensive Therapie?
In Lehrbüchern der Inneren Medizin wird vermittelt, dass bei der Mehrzahl der Patienten mit arterieller Hypertonie keine Ursache für den Blutdruckanstieg nachgewiesen werden kann. Diese Patienten werden in die Rubrik „essenzielle” Hypertonie eingeteilt. Sekundäre Hypertonieformen sind demnach sehr selten. Da die arterielle Hypertonie aber durch Adipositas hervorgerufen oder verstärkt wird, ist diese Sichtweise insbesondere vor dem Hintergrund der massiven Zunahme der Adipositas-Prävalenz in den letzten Jahren kritisch zu hinterfragen.
- 1 January 2009
- Published by Georg Thieme Verlag KG in Adipositas - Ursachen, Folgeerkrankungen, Therapie
- Vol. 03 (03) , 158-163
Angriffspunkt für eine antihypertensive Therapie?
In Lehrbüchern der Inneren Medizin wird vermittelt, dass bei der Mehrzahl der Patienten mit arterieller Hypertonie keine Ursache für den Blutdruckanstieg nachgewiesen werden kann. Diese Patienten werden in die Rubrik „essenzielle” Hypertonie eingeteilt. Sekundäre Hypertonieformen sind demnach sehr selten. Da die arterielle Hypertonie aber durch Adipositas hervorgerufen oder verstärkt wird, ist diese Sichtweise insbesondere vor dem Hintergrund der massiven Zunahme der Adipositas-Prävalenz in den letzten Jahren kritisch zu hinterfragen.
- 1 March 2006
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 1 (2) , 255-264
Obesity and the renin– angiotensin–aldosterone system
The renin-angiotensin-aldosterone system (RAAS) is a key regulator of cardiovascular function. RAAS activity is upregulated in obesity despite concurrent renal sodium retention, which is a hallmark and principle determinant of obesity-associated hypertension. The contribution of adipose tissue to increased angiotensinogen and aldosterone plasma levels in obesity is probably due to the secretion of angiotensinogen and, as yet, unidentified aldosterone secretagogues by adipocytes. Increased circulating renin activity, on the other hand, is probably due to increased sympathetic activity in the obese. Modest weight reduction significantly reduces RAAS activity by uncertain mechanisms. Pharmacological blockade of the RAAS yielded promising results, both with regard to cardiovascular function and metabolic complications of obesity. These studies suggest that the activated RAAS is a prime pharmacological target for reducing the cardiometabolic risk in obese patients.
- 1 March 2006
- Published by Taylor & Francis in Expert Review of Endocrinology & Metabolism
- Vol. 1 (2) , 255-264
Obesity and the renin– angiotensin–aldosterone system
The renin-angiotensin-aldosterone system (RAAS) is a key regulator of cardiovascular function. RAAS activity is upregulated in obesity despite concurrent renal sodium retention, which is a hallmark and principle determinant of obesity-associated hypertension. The contribution of adipose tissue to increased angiotensinogen and aldosterone plasma levels in obesity is probably due to the secretion of angiotensinogen and, as yet, unidentified aldosterone secretagogues by adipocytes. Increased circulating renin activity, on the other hand, is probably due to increased sympathetic activity in the obese. Modest weight reduction significantly reduces RAAS activity by uncertain mechanisms. Pharmacological blockade of the RAAS yielded promising results, both with regard to cardiovascular function and metabolic complications of obesity. These studies suggest that the activated RAAS is a prime pharmacological target for reducing the cardiometabolic risk in obese patients.
- Top Cited Papers
- 1 October 2005
- Published by American Diabetes Association in Diabetes
- Vol. 54 (10) , 2838-2843
Activation of the Peripheral Endocannabinoid System in Human Obesity
Obesity is the main risk factor for the development of type 2 diabetes. Activation of the central endocannabinoid system increases food intake and promotes weight gain. Blockade of the cannabinoid type 1 (CB-1) receptor reduces body weight in animals by central and peripheral actions; the role of the peripheral endocannabinoid system in human obesity is now being extensively investigated. We measured circulating endocannabinoid concentrations and studied the expression of CB-1 and the main degrading enzyme, fatty acid amide hydrolase (FAAH), in adipose tissue of lean (n = 20) and obese (n = 20) women and after a 5% weight loss in a second group of women (n = 17). Circulating levels of anandamide and 1/2-arachidonoylglycerol were increased by 35 and 52% in obese compared with lean women (P < 0.05). Adipose tissue mRNA levels were reduced by −34% for CB-1 and −59% for FAAH in obese subjects (P < 0.05). A strong negative correlation was found between FAAH expression in adipose tissue and circulating endocannabinoids. Circulating endocannabinoids and CB-1 or FAAH expression were not affected by 5% weight loss. The expression of CB-1 and FAAH was increased in mature human adipocytes compared with in preadipocytes and was found in several human tissues. Our findings support the presence of a peripheral endocannabinoid system that is upregulated in human obesity.
- 1 October 2005
- Published by American Diabetes Association in Diabetes
- Vol. 54 (10) , 2838-2843
Top Cited PapersActivation of the Peripheral Endocannabinoid System in Human Obesity
Obesity is the main risk factor for the development of type 2 diabetes. Activation of the central endocannabinoid system increases food intake and promotes weight gain. Blockade of the cannabinoid type 1 (CB-1) receptor reduces body weight in animals by central and peripheral actions; the role of the peripheral endocannabinoid system in human obesity is now being extensively investigated. We measured circulating endocannabinoid concentrations and studied the expression of CB-1 and the main degrading enzyme, fatty acid amide hydrolase (FAAH), in adipose tissue of lean (n = 20) and obese (n = 20) women and after a 5% weight loss in a second group of women (n = 17). Circulating levels of anandamide and 1/2-arachidonoylglycerol were increased by 35 and 52% in obese compared with lean women (P < 0.05). Adipose tissue mRNA levels were reduced by −34% for CB-1 and −59% for FAAH in obese subjects (P < 0.05). A strong negative correlation was found between FAAH expression in adipose tissue and circulating endocannabinoids. Circulating endocannabinoids and CB-1 or FAAH expression were not affected by 5% weight loss. The expression of CB-1 and FAAH was increased in mature human adipocytes compared with in preadipocytes and was found in several human tissues. Our findings support the presence of a peripheral endocannabinoid system that is upregulated in human obesity.
- Top Cited Papers
- 1 March 2005
- Published by Wolters Kluwer Health in Hypertension
- Vol. 45 (3) , 356-362
Weight Loss and the Renin-Angiotensin-Aldosterone System
The renin-angiotensin-aldosterone system has been causally implicated in obesity-associated hypertension. We studied the influence of obesity and weight reduction on the circulating and adipose tissue renin-angiotensin-aldosterone system in menopausal women. Blood samples were analyzed for angiotensinogen, renin, aldosterone, angiotensin-converting enzyme activity, and angiotensin II. In adipose tissue biopsy samples, we analyzed angiotensinogen, renin, renin-receptor, angiotensin-converting enzyme, and angiotensin II type-1 receptor gene expression. Obese women (n=19) had higher circulating angiotensinogen, renin, aldosterone, and angiotensin-converting enzyme than lean women (n=19), and lower angiotensinogen gene expression in adipose tissue. Seventeen women successfully participated in a weight reduction protocol over 13 weeks to reduce daily caloric intake by 600 kcal. Body weight was reduced by −5%, as were angiotensinogen levels by −27%, renin by −43%, aldosterone by −31%, angiotensin-converting enzyme activity by −12%, and angiotensinogen expression by −20% in adipose tissue (all P r =0.74; P <0.001). Weight and renin-angiotensin-aldosterone system reductions were accompanied by a −7-mm Hg reduced systolic ambulatory blood pressure. These data suggest that a 5% reduction in body weight can lead to a meaningfully reduced renin-angiotensin-aldosterone system in plasma and adipose tissue, which may contribute to the reduced blood pressure.
- 1 March 2005
- Published by Wolters Kluwer Health in Hypertension
- Vol. 45 (3) , 356-362
Top Cited PapersWeight Loss and the Renin-Angiotensin-Aldosterone System
The renin-angiotensin-aldosterone system has been causally implicated in obesity-associated hypertension. We studied the influence of obesity and weight reduction on the circulating and adipose tissue renin-angiotensin-aldosterone system in menopausal women. Blood samples were analyzed for angiotensinogen, renin, aldosterone, angiotensin-converting enzyme activity, and angiotensin II. In adipose tissue biopsy samples, we analyzed angiotensinogen, renin, renin-receptor, angiotensin-converting enzyme, and angiotensin II type-1 receptor gene expression. Obese women (n=19) had higher circulating angiotensinogen, renin, aldosterone, and angiotensin-converting enzyme than lean women (n=19), and lower angiotensinogen gene expression in adipose tissue. Seventeen women successfully participated in a weight reduction protocol over 13 weeks to reduce daily caloric intake by 600 kcal. Body weight was reduced by −5%, as were angiotensinogen levels by −27%, renin by −43%, aldosterone by −31%, angiotensin-converting enzyme activity by −12%, and angiotensinogen expression by −20% in adipose tissue (all P r =0.74; P <0.001). Weight and renin-angiotensin-aldosterone system reductions were accompanied by a −7-mm Hg reduced systolic ambulatory blood pressure. These data suggest that a 5% reduction in body weight can lead to a meaningfully reduced renin-angiotensin-aldosterone system in plasma and adipose tissue, which may contribute to the reduced blood pressure.
- Open Access
- 1 September 2004
- Published by Elsevier in Journal of Lipid Research
- Vol. 45 (9) , 1640-1648
Regulation of the nitric oxide system in human adipose tissue
- 1 September 2004
- Published by Elsevier in Journal of Lipid Research
- Vol. 45 (9) , 1640-1648
Open AccessRegulation of the nitric oxide system in human adipose tissue
- 1 January 2004
- Published by Wiley in Obesity Research
- Vol. 12 (1) , 9-17
Regulation of 11β‐HSD Genes in Human Adipose Tissue: Influence of Central Obesity and Weight Loss
Objectives: The activity of adipose 11β‐hydroxysteroid dehydrogenase (11β‐HSD) 1 is increased in obese subjects, and animal data suggest that increased cortisol formation in adipose tissue contributes to the development of the metabolic syndrome. The aim of this study was to determine whether up‐regulation of human adipose 11β‐HSD1 in obesity can also be found at the gene expression level.Research Methods and Procedures: 11β‐HSD gene expression in subcutaneous adipose tissue biopsies of 70 postmenopausal women was studied by real‐time reverse‐transcription polymerase chain reaction. The influence of weight reduction and in vitro effects of several modulators of adipocyte gene expression on 11β‐HSD genes in human adipocytes were also studied.Results: The 11β‐HSD1 gene was highly expressed in human adipose tissue. 11β‐HSD2 mRNA was also detectable at lower levels. Adipose 11β‐HSD1 gene expression was increased by two‐fold and was positively correlated with waist circumference and homeostasis model assessment index of insulin resistance. 11β‐HSD2 gene expression was reduced by half in obese women. Weight reduction did not change gene expression levels of 11β‐HSD1 or 11β‐HSD2. Cortisol increased 11β‐HSD1 gene expression in isolated human adipocytes in vitro, whereas estradiol, triiodothyronine, angiotensin II, and pioglitazone had no influence.Discussion: Our data suggest that increased expression of the 11β‐HSD1 gene is associated with metabolic abnormalities in obese women and that increased expression of this gene may contribute to the previously reported increased local conversion of cortisone to cortisol in adipose tissue of obese individuals.
- 1 January 2004
- Published by Wiley in Obesity Research
- Vol. 12 (1) , 9-17
Regulation of 11β‐HSD Genes in Human Adipose Tissue: Influence of Central Obesity and Weight Loss
Objectives: The activity of adipose 11β‐hydroxysteroid dehydrogenase (11β‐HSD) 1 is increased in obese subjects, and animal data suggest that increased cortisol formation in adipose tissue contributes to the development of the metabolic syndrome. The aim of this study was to determine whether up‐regulation of human adipose 11β‐HSD1 in obesity can also be found at the gene expression level.Research Methods and Procedures: 11β‐HSD gene expression in subcutaneous adipose tissue biopsies of 70 postmenopausal women was studied by real‐time reverse‐transcription polymerase chain reaction. The influence of weight reduction and in vitro effects of several modulators of adipocyte gene expression on 11β‐HSD genes in human adipocytes were also studied.Results: The 11β‐HSD1 gene was highly expressed in human adipose tissue. 11β‐HSD2 mRNA was also detectable at lower levels. Adipose 11β‐HSD1 gene expression was increased by two‐fold and was positively correlated with waist circumference and homeostasis model assessment index of insulin resistance. 11β‐HSD2 gene expression was reduced by half in obese women. Weight reduction did not change gene expression levels of 11β‐HSD1 or 11β‐HSD2. Cortisol increased 11β‐HSD1 gene expression in isolated human adipocytes in vitro, whereas estradiol, triiodothyronine, angiotensin II, and pioglitazone had no influence.Discussion: Our data suggest that increased expression of the 11β‐HSD1 gene is associated with metabolic abnormalities in obese women and that increased expression of this gene may contribute to the previously reported increased local conversion of cortisone to cortisol in adipose tissue of obese individuals.
- 10 July 2003
- Vol. 145, 44
[What effect does losing weight have on hypertension?].
- 1 June 2003
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 35 (6) , 807-825
The adipose-tissue renin–angiotensin–aldosterone system: role in the metabolic syndrome?
- 1 June 2003
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 35 (6) , 807-825
The adipose-tissue renin–angiotensin–aldosterone system: role in the metabolic syndrome?
- 1 April 2003
- Published by American Diabetes Association in Diabetes
- Vol. 52 (4) , 942-947
Association Between Adiponectin and Mediators of Inflammation in Obese Women
Low plasma levels of the anti-inflammatory factor adiponectin characterize obesity and insulin resistance. To elucidate the relationship between plasma levels of adiponectin, adiponectin gene expression in adipose tissue, and markers of inflammation, we obtained blood samples, anthropometric measures, and subcutaneous adipose tissue samples from 65 postmenopausal healthy women. Adiponectin plasma levels and adipose-tissue gene expression were significantly lower in obese subjects and inversely correlated with obesity-associated variables, including high-sensitive C-reactive protein (hs-CRP) and interleukin-6 (IL-6). Despite adjustment for obesity-associated variables, plasma levels of adiponectin were significantly correlated to adiponectin gene expression (partial r = 0.38, P < 0.05). Furthermore, the inverse correlation between plasma levels of hs-CRP and plasma adiponectin remained significant despite correction for obesity-associated variables (partial r = −0.32, P < 0.05), whereas the inverse correlation between adiponectin plasma levels or adiponectin gene expression in adipose tissue with plasma IL-6 were largely dependent on the clustering of obesity-associated variables. In conclusion, our data suggest a transcriptional mechanism leading to decreased adiponectin plasma levels in obese women and demonstrate that low levels of adiponectin are associated with higher levels of hs-CRP and IL-6, two inflammatory mediators and markers of increased cardiovascular risk.
- 1 April 2003
- Published by American Diabetes Association in Diabetes
- Vol. 52 (4) , 942-947
Association Between Adiponectin and Mediators of Inflammation in Obese Women
Low plasma levels of the anti-inflammatory factor adiponectin characterize obesity and insulin resistance. To elucidate the relationship between plasma levels of adiponectin, adiponectin gene expression in adipose tissue, and markers of inflammation, we obtained blood samples, anthropometric measures, and subcutaneous adipose tissue samples from 65 postmenopausal healthy women. Adiponectin plasma levels and adipose-tissue gene expression were significantly lower in obese subjects and inversely correlated with obesity-associated variables, including high-sensitive C-reactive protein (hs-CRP) and interleukin-6 (IL-6). Despite adjustment for obesity-associated variables, plasma levels of adiponectin were significantly correlated to adiponectin gene expression (partial r = 0.38, P < 0.05). Furthermore, the inverse correlation between plasma levels of hs-CRP and plasma adiponectin remained significant despite correction for obesity-associated variables (partial r = −0.32, P < 0.05), whereas the inverse correlation between adiponectin plasma levels or adiponectin gene expression in adipose tissue with plasma IL-6 were largely dependent on the clustering of obesity-associated variables. In conclusion, our data suggest a transcriptional mechanism leading to decreased adiponectin plasma levels in obese women and demonstrate that low levels of adiponectin are associated with higher levels of hs-CRP and IL-6, two inflammatory mediators and markers of increased cardiovascular risk.